Literature DB >> 34359684

The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer.

Rozana Abdul Rahman1, Angela Lamarca2, Richard A Hubner2, Juan W Valle3, Mairéad G McNamara3.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and is projected to be the second most common cause of cancer-related death by 2030, with an overall 5-year survival rate between 7% and 9%. Despite recent advances in surgical, chemotherapy, and radiotherapy techniques, the outcome for patients with PDAC remains poor. Poor prognosis is multifactorial, including the likelihood of sub-clinical metastatic disease at presentation, late-stage at presentation, absence of early and reliable diagnostic biomarkers, and complex biology surrounding the extensive desmoplastic PDAC tumour micro-environment. Microbiota refers to all the microorganisms found in an environment, whereas microbiome is the collection of microbiota and their genome within an environment. These organisms reside on body surfaces and within mucosal layers, but are most abundantly found within the gut. The commensal microbiome resides in symbiosis in healthy individuals and contributes to nutritive, metabolic and immune-modulation to maintain normal health. Dysbiosis is the perturbation of the microbiome that can lead to a diseased state, including inflammatory bowel conditions and aetiology of cancer, such as colorectal and PDAC. Microbes have been linked to approximately 10% to 20% of human cancers, and they can induce carcinogenesis by affecting a number of the cancer hallmarks, such as promoting inflammation, avoiding immune destruction, and microbial metabolites can deregulate host genome stability preceding cancer development. Significant advances have been made in cancer treatment since the advent of immunotherapy. The microbiome signature has been linked to response to immunotherapy and survival in many solid tumours. However, progress with immunotherapy in PDAC has been challenging. Therefore, this review will focus on the available published evidence of the microbiome association with PDAC and explore its potential as a target for therapeutic manipulation.

Entities:  

Keywords:  microbiome; pancreatic ductal adenocarcinoma (PDAC); therapeutic manipulation

Year:  2021        PMID: 34359684     DOI: 10.3390/cancers13153779

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC).

Authors:  Roseanna C Wheatley; Juan W Valle; Mairéad G McNamara
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

2.  Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study.

Authors:  Sara Massironi; Federica Facciotti; Federica Cavalcoli; Chiara Amoroso; Emanuele Rausa; Giovanni Centonze; Fulvia Milena Cribiù; Pietro Invernizzi; Massimo Milione
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

Review 3.  The Microbiome in Pancreatic Cancer-Implications for Diagnosis and Precision Bacteriophage Therapy for This Low Survival Disease.

Authors:  Mwila Kabwe; Stuart Dashper; Joseph Tucci
Journal:  Front Cell Infect Microbiol       Date:  2022-05-19       Impact factor: 6.073

Review 4.  Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target.

Authors:  Tao Zhang; Guangqi Gao; Hafiz Arbab Sakandar; Lai-Yu Kwok; Zhihong Sun
Journal:  Front Nutr       Date:  2022-02-15

Review 5.  Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis.

Authors:  Ashna Gupta; Ravi Chauhan; Tarang Sharma; Ajaz A Bhat; Sabah Nisar; Sheema Hashem; Sabah Akhtar; Aamir Ahmad; Mohammad Haris; Mayank Singh; Shahab Uddin
Journal:  Cancer Metastasis Rev       Date:  2022-05-05       Impact factor: 9.237

Review 6.  Impact of microbiota-immunity axis in pancreatic cancer management.

Authors:  Ilenia Bartolini; Giulia Nannini; Matteo Risaliti; Francesco Matarazzo; Luca Moraldi; Maria Novella Ringressi; Antonio Taddei; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2022-08-28       Impact factor: 5.374

Review 7.  Microbiota in Pancreatic Diseases: A Review of the Literature.

Authors:  Tommaso Schepis; Sara S De Lucia; Enrico C Nista; Vittoria Manilla; Giulia Pignataro; Veronica Ojetti; Andrea Piccioni; Antonio Gasbarrini; Francesco Franceschi; Marcello Candelli
Journal:  J Clin Med       Date:  2021-12-17       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.